10/698,737

STN STRUCTURE SEARCH

=> d ibib abs hitstr 1-5

ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2003:757709 CAPLUS

DOCUMENT NUMBER:

139:281336

TITLE:

Process for preparing crystalline

Form I of cabergoline

INVENTOR(S):

Sheikh, Ahmad Y.; Tomasi, Attilio

PATENT ASSIGNEE(S):

Pharmacia Corporation, USA; Pharmacia Italia S.P.A.

SOURCE:

PCT Int. Appl., 23 pp.

CODEN: PIXXD2 Patent

DOCUMENT TYPE: LANGUAGE:

English

3

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.			KIND DATE				APPLICATION NO.					DATE					
	-								-								
WO	2003	0784	33	A	1 .	2003	0925		Mo	2 O	03-E	P262	8	2003	0310		
	W :	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FΙ,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	ΙL,	IN,	IS,	JP,	KΕ,	KG,	KΡ,	KR,	ΚŻ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NO,	ΝZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	TZ,
		UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW,	AM,	AZ,	BY,	KG,	KΖ,	MD,
		RU,	TJ,	TM													
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	ΑT,	BE,	BG,
		CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	ΗU,	ΙE,	ΙT,	LU,	MC,
		NL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,
		GW,	ML,	MR,	NE,	SN,	TD,	TG									
PRIORITY	APP	LN.	INFO	. :				1	US 2	002-3	3645	67P	Р	2002	0315		
								1	JS 20	002-	4101	63P	Ρ	2002	0912		

AΒ A process for producing crystalline Form I of cabergoline comprises the preparation of Form V using heptane as precipitation solvent,

exclusive conversion into crystalline Form I of

cabergoline. The present crystallization process from toluene-heptane solvent system for Form V involves 'reverse addition' of toluene-cabergoline concentrate to

cold heptane.

81409-90-7, Cabergoline

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(process for preparation of crystalline Form I of cabergoline using toluene-heptane solvent system)

81409-90-7 CAPLUS RN

Ergoline-8-carboxamide, N-[3-(dimethylamino)propyl]-N-CN [(ethylamino)carbonyl]-6-(2-propenyl)-, (8β) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

3

ACCESSION NUMBER:

2003:757674 CAPLUS

DOCUMENT NUMBER:

139:265794

TITLE:

Process for preparing the crystalline

form I of cabergoline

INVENTOR(S):

Sheikh, Ahmad Y.

PATENT ASSIGNEE(S):

Pharmacia Corporation, USA

SOURCE:

PCT Int. Appl., 17 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

English

PATENT INFORMATION:

PAT	ENT	NO.		KI	ND	DATE			A	PPLI	CATI	ON NO	Э.	DATE			
					- -				-								
WO	2003	0783	92	A.	2	2003	0925		W	0 20	03 - U	S713	8	2003	0310		
WO	2003	0783	92	A.	3	2003	1211		•								
	W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	ΙL,	IN,	IS,	JP,	KE,	KG,	ΚP,	KR,	KZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	TZ,
		UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW,	AM,	ΑZ,	BY,	KG,	KΖ,	MD,
		RU,	ТJ,	TM													
	RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AT,	BE,	BG,
		CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	ΙE,	IT,	LU,	MC,
		NL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,
		GW,	ML,	MR,	ΝE,	SN,	TD,	TG									
TRITTY	VDD.	T.N.	TNEO					1	TC 21	202	2615	(7D	D	2002	0 2 1 E		

PRIORITY APPLN. INFO.:

US 2002-364567P P 20020315

US 2002-410253P P 20020912

AB A process for producing crystalline form I of cabergoline comprises crystallization of the desired form from a toluene/hepta

comprises crystallization of the desired form from a toluene/heptane or toluene/hexane mixture starting from raw cabergoline, followed by recovery and removal of the solvent from the resulting toluene solvate

Form X so as to convert it into form I. The solvate

 ${f form}$ X of cabergoline and its preparation are also provided.

IT **81409-90-7**, Cabergoline

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); PROC (Process)

(process for preparing the ${f crystalline}$ form I of cabergoline)

RN 81409-90-7 CAPLUS

CN Ergoline-8-carboxamide, N-[3-(dimethylamino)propyl]-N[(ethylamino)carbonyl]-6-(2-propenyl)-, (8β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2001:730740 CAPLUS

DOCUMENT NUMBER:

135:262285

TITLE:

Crystalline form II of cabergoline

INVENTOR(S):

Tomasi, Attilio; Magenes, Stefania; Ramella, Giuliano;

Ungari, Mario; Pandolfi, Marco Pharmacia & Upjohn S.p.A., Italy

PATENT ASSIGNEE(S):

PCT Int. Appl., 18 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

WO 2001072747 A1 20011004 WO 2001-EP3098 20010319 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH,				
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH,				
	CH, CN,			
	GM, HR,			
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,	LS, LT,			
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,	RO, RU,			
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,	UZ, VN,			
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE,	CH, CY,			
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,	TR, BF,			
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001042482 A5 20011008 AU 2001-42482 20010319				
BR 2001009508 A 20021217 BR 2001-9508 20010319				
EP 1280803 A1 20030205 EP 2001-915373 20010319				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, E	MC, PT,			
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003528874 T2 20030930 JP 2001-570657 20010319				
NO 2002004527 A 20020920 NO 2002-4527 20020920				
US 2003187013 A1 20031002 US 2003-239562 20030116				
US 6673806 B2 20040106				

PRIORITY APPLN. INFO.:

GB 2000-7307

A 20000324

WO 2001-EP3098 W 20010319

The crystalline form II of cabergoline, a pharmaceutical

composition containing the form and a process for its preparation are disclosed. The

process comprises crystallization from a solution of cabergoline in an organic solvent

at low temps. or submitting to a slurry procedure a mixture of cabergoline forms I and II in a solvent at a temperature below 30°. Thus,

cabergoline was dissolved in di-Et ether, carbon and sodium sulfate and the mixture was filtered. The solution was concentrated to 80 mL and the solution was

cooled to -5°. The suspension was filtered under vacuum and the crystals were then dried.

81409-90-7, Cabergoline

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES

(crystalline form II of cabergoline)

RN 81409-90-7 CAPLUS

Ergoline-8-carboxamide, N-[3-(dimethylamino)propyl]-N-CN

[(ethylamino)carbonyl]-6-(2-propenyl)-, (8β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2001:730739 CAPLUS

DOCUMENT NUMBER:

135:262284

TITLE:

Crystalline form VII of

cabergoline

INVENTOR(S):

Candiani, Ilaria; Budelli, Raffaella; Pandolfi, Marco;

Ungari, Mario

PATENT ASSIGNEE(S):

Pharmacia & Upjohn S.p.A., Italy

SOURCE:

PCT Int. Appl., 15 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO. DATE

```
WO 2001072746
                      Α1
                             20011004
                                           WO 2001-EP2969
                                                              20010315
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                      A5 20011008
                                          AU 2001-52211
     AU 2001052211
                                                              20010315
     EP 1265894
                       Α1
                             20021218
                                           EP 2001-925471
                                                              20010315
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
         R:
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                             20030930
                                           JP 2001-570656
     JP 2003528873
                       T2
                                                              20010315
     US 2003144516
                       Α1
                             20030731
                                            US 2002-221165
                                                              20020918
     US 6680327
                             20040120
PRIORITY APPLN. INFO.:
                                         GB 2000-7309
                                                             20000324
                                         WO 2001-EP2969
                                                           W 20010315
     The crystalline form VII of cabergoline, a pharmaceutical
     composition containing the form and a process for its preparation are
disclosed. The
     process may comprise a slurry procedure by using the form I or mixture of
     forms I and VII in a solvent at a temperature above 30°. Thus,
     cabergoline was dissolved in 1,4-dioxane at 40°, the final solution
     was cooled to -5° and the solid was filtered and dried at
     30-65°. The crystals of the form VII were obtained.
IT
     81409-90-7, Cabergoline
     RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
     (Uses)
        (crystalline form VII of cabergoline)
RN
     81409-90-7 CAPLUS
     Ergoline-8-carboxamide, N-[3-(dimethylamino)propyl]-N-
CN
     [(ethylamino)carbonyl]-6-(2-propenyl)-, (8\beta)- (9CI) (CA INDEX NAME)
```

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

6

ACCESSION NUMBER:

2001:713349 CAPLUS

DOCUMENT NUMBER:

135:242388

TITLE:

Process for preparing crystalline

form I of cabergoline Tomasi, Attilio; Magenes, Stefania; Ungari, Mario; INVENTOR(S): Ramella, Giuliano; Pallanza, Gianfranco Pharmacia & Upjohn S.p.A., Italy PATENT ASSIGNEE(S): PCT Int. Appl., 18 pp. SOURCE: CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE _____ -----WO 2001070740 A1 20010927 WO 2001-EP3099 20010319 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG BR 2001009507 20021210 BR 2001-9507 Α 20010319 EP 1272489 Α1 20030108 EP 2001-936098 20010319 EP 1272489 20030924 В1 AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR JP 2003528100 T2 20030924 JP 2001-568941 20010319 AT 250601 AT 2001-1936098 Ε 20031015 20010319 ZA 2002006045 ZA 2002-6045 Α 20030729 20020729 NO 2002004321 Α 20020910 NO 2002-4321 20020910 US 2003149067 US 2003-239636 Α1 20030807 20030203 PRIORITY APPLN. INFO.: GB 2000-7308 Α 20000324 WO 2001-EP3099 W 20010319 A process for producing crystalline form I of cabergoline, which process comprises crystallization of the desired form from a toluene/diethyl ether mixture comprising raw cabergoline, followed by recovery and drying of the resulting crystals. A new solvate, form V of cabergoline, which is a 2:1 solvate of cabergoline and toluene and is a useful as an intermediate for preparing crystalline form I of cabergoline, was also prepared 81409-90-7P, Cabergoline RL: PUR (Purification or recovery); PREP (Preparation) (process for preparing crystalline of cabergoline via formation of cabergoline toluene solvate (2:1)) RN 81409-90-7 CAPLUS Ergoline-8-carboxamide, N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-, (8β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => d his

(FILE 'HOME' ENTERED AT 12:17:41 ON 09 APR 2004)

FILE 'REGISTRY' ENTERED AT 12:17:49 ON 09 APR 2004

E CABERGOLINE/CN

L1 1 S E3

FILE 'CAPLUS' ENTERED AT 12:18:41 ON 09 APR 2004

L2 232 S L1

L3 159812 S CRYSTALLINE FORM? OR SOLVATE FORM? OR POLYMORPH?

L4 5 S L2 AND L3

=> d 11

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN 81409-90-7 REGISTRY

CN Ergoline-8-carboxamide, N-[3-(dimethylamino)propyl]-N [(ethylamino)carbonyl]-6-(2-propenyl)-, (8β)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:

CN Indolo[4,3-fg]quinoline, ergoline-8-carboxamide deriv.

OTHER NAMES:

CN Cabaser

CN Cabergoline

CN Dostinex

CN Galastop

CN Sogilen

FS STEREOSEARCH

MF C26 H37 N5 O2

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IMSCOSEARCH,
IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT,
PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU

10/698,737

=>

(*File contains numerically searchable property data) Other Sources: WHO

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

231 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

232 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10/668,326

Other Sources: WHO

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

231 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

232 REFERENCES IN FILE CAPLUS (1907 TO DATE)



PALM INTRANET

Day: Friday Date: 4/9/2004 Time: 12:24:58

Inventor Name Search Result

Your Search was:

Last Name = TOMASI First Name = ATTILIO

Application#	Patent#	Status	Date Filed	Title	Inventor Name 7
60410163	Not Issued	020	09/12/2002	PROCESS FOR PREPARING CRYSTALLINE FORM I OF CABERGOLINE	TOMASI, ATTILIO
60360684	Not Issued	159	03/01/2002	CRYSTALLINE POLYMORPHIC FORM OF IRINOTECAN HYDROCHLORIDE	TOMASI, ATTILIO
<u>10698737</u>	Not Issued	030	10/31/2003	PROCESS FOR PREPARING CRYSTALLINE FORM I OF CABERGOLINE	TOMASI, ATTILIO
10698664	Not Issued	041	10/31/2003	CRYSTALLINE FORM II OF CABERGOLINE	TOMASI, ATTILIO
10239636	6727363	150	02/03/2003	PROCESS FOR PREPARING CRYSTALLINE FROM I OF CABERGOLINE	TOMASI, ATTILIO
10239562	6673806	150	01/16/2003	CRYSTALLINE FORM II CABERGOLINE	TOMASI, ATTILIO
07982979	Not Issued	161	11/30/1992	PROCESS FOR 3-AMINO-RIFAMYCIN	TOMASI, ATTILIO

Inventor Search Completed: No Records to Display.

	Last Name	First Name		
Search Another:	Tomasi	Attilio		
Inventor		Search	*************	

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page